The Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2200, Copenhagen N, Denmark.
Pflugers Arch. 2011 Oct;462(4):529-43. doi: 10.1007/s00424-011-1005-7. Epub 2011 Aug 3.
It is uncertain if downregulation of β-adrenoceptor signaling pathway is promoted by an enhanced adrenergic tone at an early stage of cardiac disease, or it develops secondary to detrimental local myocardial changes in advanced heart failure. We examined the integrity of β-adrenoceptor signaling pathway upon chronic infusion of isoproterenol, a β-adrenoceptor agonist, at a dose producing no structural left ventricular (LV) remodeling and systolic dysfunction. Subcutaneous isoproterenol infusion (400 μg kg(-1) h(-1) over 16 days) to guinea pigs using osmotic minipumps produced no change in cardiac weights, LV internal dimensions, myocyte cross-sectional area, extent of interstitial fibrosis, and basal contractile function. Isolated, perfused heart preparations from isoproterenol-treated guinea pigs exhibited attenuated responsiveness to acute β-adrenoceptor stimulation, as evidenced by reduced LV developed pressure increase, less shortening of LV epicardial monophasic action potential and effective refractory period, and less myocardial cyclic adenosine monophosphate elevation, in response to isoproterenol exposure, when compared to saline-treated controls. Pharmacological responses to forskolin, an activator of the adenylate cyclase catalytic subunit, were well preserved in isoproterenol-treated hearts. Downregulation of β-adrenoceptor-mediated effects upon chronic isoproterenol infusion was associated with markedly reduced stimulatory G-protein α-subunit (G(sα)) myocardial expression levels. No change in expression levels of β-adrenoceptors, G-protein-coupled receptor kinase 2, inhibitory G-protein α-subunit (G(iα2)), and Ca(v)1.2 and K(v)7.1 ion channels was determined in isoproterenol-treated hearts. We therefore conclude that sustained adrenergic overstimulation may promote downregulation of myocardial β-adrenoceptor-mediated effects independently of structural LV remodeling and systolic failure, an effect attributed to β-adrenoceptor uncoupling from adenylate cyclase due to reduced G(sα)-protein expression.
β-肾上腺素能受体信号通路的下调是否是由心脏疾病早期增强的肾上腺素能张力促进的,或者它是否是在晚期心力衰竭时由于局部心肌的有害变化而发展的,目前尚不确定。我们检查了在慢性异丙肾上腺素输注(β-肾上腺素能受体激动剂,剂量不引起左心室(LV)结构重塑和收缩功能障碍)期间,β-肾上腺素能受体信号通路的完整性。使用渗透微型泵向豚鼠皮下输注异丙肾上腺素(16 天内 400μg/kg/h)不会改变心脏重量、LV 内部尺寸、心肌细胞横截面积、间质纤维化程度和基础收缩功能。与盐水处理的对照组相比,来自异丙肾上腺素处理的豚鼠的分离的灌注心脏制剂对急性β-肾上腺素受体刺激的反应性降低,表现为 LV 发展压增加减少,LV 心外膜单相动作电位和有效不应期缩短减少,以及心肌环腺苷单磷酸升高减少,对异丙肾上腺素暴露的反应。异丙肾上腺素处理的心脏中,福斯柯林(激活腺苷酸环化酶催化亚单位的药物)的药理学反应得到很好的保留。慢性异丙肾上腺素输注后β-肾上腺素能受体介导的作用下调与刺激 G 蛋白α-亚基(G(sα))心肌表达水平明显降低有关。在异丙肾上腺素处理的心脏中,未检测到β-肾上腺素受体、G 蛋白偶联受体激酶 2、抑制 G 蛋白α-亚基(G(iα2))和 Ca(v)1.2 和 K(v)7.1 离子通道的表达水平发生变化。因此,我们得出结论,持续的肾上腺素能过度刺激可能会促进心肌β-肾上腺素能受体介导的作用下调,而与 LV 结构重塑和收缩衰竭无关,这种作用归因于由于 G(sα)-蛋白表达减少,β-肾上腺素能受体与腺苷酸环化酶解偶联。